A meta-analysis published in JAMA found that outpatients whose cystatin C-based kidney function estimate was significantly lower than their creatinine-based estimate faced higher risks of death, cardiovascular events, and kidney failure. The study, which included 821,327 outpatients and 39,639 inpatients, determined that a 30% or greater difference between these estimates correlated with worse outcomes over an 11-year follow-up. This analysis, part of the Chronic Kidney Disease Prognosis Consortium (CKD-PC), involved 23 outpatient cohorts and 2 inpatient cohorts, with participants having concurrent creatinine and cystatin C measurements.
The researchers defined a large negative difference as an estimated glomerular filtration rate based on cystatin C (eGFRcys) at least 30% lower than the creatinine-based rate (eGFRcr). This discrepancy was more prevalent in hospitalized patients, with 35% exhibiting such a difference, compared to 11% of outpatients. Among outpatients, 3.8% showed a large positive difference, highlighting the variability in discordance.
Discordance in Kidney Function Markers
Among outpatients, factors such as older age, diabetes, heart failure, peripheral artery disease, chronic obstructive pulmonary disease, liver disease, current smoking, and higher albuminuria were associated with a higher likelihood of a large negative difference. The study also observed significant variation across cohorts, with rates ranging from 2.8% to 49.8%. Lower eGFRcr was linked to this discrepancy, though the pattern was inconsistent across eGFRcr categories.
Patients with a large negative gap experienced higher rates of all-cause mortality (28.4 vs. 16.8 per 1,000 person-years; HR, 1.69; 95% CI, 1.57-1.82) and cardiovascular mortality (6.1 vs. 3.8 per 1,000 person-years; HR, 1.61; 95% CI, 1.48-1.76). They also faced increased risks of atherosclerotic cardiovascular disease (13.3 vs. 9.8 per 1,000 person-years; HR, 1.35; 95% CI, 1.27-1.44), heart failure (13.2 vs. 8.6; HR, 1.54; 95% CI, 1.40-1.68), and kidney failure requiring treatment (2.7 vs. 2.1; HR, 1.29; 95% CI, 1.13-1.47).
Read Also: Low Colorectal Cancer Risk After Endoscopic Mucosal Resection
These models were adjusted for demographics, comorbidities, body mass index, eGFRcr category, and albuminuria. Notably, the kidney failure association reversed (HR, 0.73; 95% CI, 0.64-0.84) when models were adjusted for eGFRcr-cys instead of eGFRcr, though mortality and cardiovascular associations persisted with smaller estimates.
Implications for Clinical Practice
These findings suggest that cystatin C testing may provide a more accurate assessment of kidney function, particularly for patients with conditions like heart failure or liver disease. The authors recommend that laboratories report both eGFRcys and the combined eGFRcr-cys alongside the standard eGFRcr. This aligns with the 2024 KDIGO guideline, which advises using eGFRcr for adults at risk of chronic kidney disease (CKD) and incorporating cystatin C when available for a more precise GFR category.
However, the study had limitations. Variations in creatinine and cystatin C measurement methods, reliance on diagnosis codes for outcomes, and lack of data on factors like muscle mass could influence the results. The UK Biobank, which constituted half of the outpatient population, was over 90% White, although excluding it did not significantly alter the findings. Long-term outcomes were not evaluated in hospitalized patients.
The researchers concluded that a large negative difference in kidney function estimates was linked to higher mortality and cardiovascular risks in outpatients, emphasizing the potential value of cystatin C testing in enhancing clinical decision-making for patients with chronic kidney disease.
